Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Operating Margin (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Operating Margin for 4 consecutive years, with 41.34% as the latest value for Q4 2025.

  • Quarterly Operating Margin fell 406.0% to 41.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 41.41% through Dec 2025, up 1879.0% year-over-year, with the annual reading at 41.45% for FY2025, 1882.0% up from the prior year.
  • Operating Margin hit 41.34% in Q4 2025 for Krystal Biotech, down from 42.3% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 962.0% in Q1 2021 to a low of 303.8% in Q3 2023.
  • Historically, Operating Margin has averaged 81.93% across 4 years, with a median of 40.94% in 2025.
  • Biggest five-year swings in Operating Margin: soared 33061bps in 2024 and later plummeted -406bps in 2025.
  • Year by year, Operating Margin stood at 962.0% in 2021, then tumbled by -99bps to 7.71% in 2023, then skyrocketed by 489bps to 45.41% in 2024, then decreased by -9bps to 41.34% in 2025.
  • Business Quant data shows Operating Margin for KRYS at 41.34% in Q4 2025, 42.3% in Q3 2025, and 40.94% in Q2 2025.